14.65

3.31% +0.47

Deciphera Pharmaceuticals Inc (DCPH)

Overview News Price History Option Chain Discussions Forecast

Deciphera Pharmaceuticals Inc stock is currently priced at $14.65, with a 24-hour trading volume of 325.45K. It has seen a +3.31% increased in the last 24 hours and a -1.15% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $14.34 pivot point. If it approaches the $14.69 resistance level, significant changes may occur.

Previous Close:

$14.18

Open:

$14.21

24h Volume:

325.45K

Market Cap:

$1.18B

Revenue:

$163.36M

Net Income/Loss:

$-194.94M

P/E Ratio:

-6.234

EPS:

-2.35

Net Cash Flow:

$-147.48M

1W Performance:

-0.14%

1M Performance:

-1.15%

6M Performance:

+43.91%

1Y Performance:

+1.81%

1D Range:

$14.09

$14.84

52W Range:

$9.90

$17.73

Deciphera Pharmaceuticals Inc Stock (DCPH) Company Profile

Name

Deciphera Pharmaceuticals Inc

Sector

Healthcare (1191)

Industry

Drug Manufacturers - Specialty & Generic (4)

Phone

781-209-6400

Address

500 Totten Pond Road, 6th Floor, Waltham, MA

Employee

Twitter

@Deciphera

Next Earnings Date

2024-05-01

Latest SEC Filings

DCPH's Discussions on Twitter

Deciphera Pharmaceuticals Inc Stock (DCPH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-20-23	Resumed	JP Morgan	Neutral
Oct-30-23	Upgrade	Piper Sandler	Neutral → Overweight
Aug-10-23	Upgrade	Stifel	Hold → Buy
Jan-04-23	Upgrade	Guggenheim	Neutral → Buy
Aug-29-22	Initiated	Cowen	Outperform
Aug-05-22	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
Feb-28-22	Downgrade	Barclays	Equal Weight → Underweight
Nov-08-21	Downgrade	Barclays	Overweight → Equal Weight
Nov-08-21	Downgrade	Canaccord Genuity	Buy → Hold
Nov-08-21	Downgrade	Stifel	Buy → Hold
Nov-05-21	Downgrade	Truist	Buy → Hold
Sep-30-21	Resumed	Stifel	Buy
Mar-31-21	Initiated	Credit Suisse	Outperform
Feb-10-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Dec-03-20	Initiated	Stifel	Buy
Sep-14-20	Resumed	JP Morgan	Neutral
May-07-20	Downgrade	Nomura	Buy → Neutral
Mar-04-20	Initiated	Barclays	Overweight
Dec-20-19	Reiterated	Jefferies	Buy
Oct-29-19	Upgrade	SVB Leerink	Underperform → Mkt Perform
Oct-22-19	Initiated	JMP Securities	Mkt Outperform
Oct-03-19	Initiated	H.C. Wainwright	Buy
Sep-30-19	Initiated	Jefferies	Buy
Jul-18-19	Initiated	Deutsche Bank	Buy
Dec-31-18	Upgrade	B. Riley FBR	Neutral → Buy
Sep-25-18	Initiated	Leerink Partners	Underperform
Aug-29-18	Initiated	Raymond James	Outperform
Jul-05-18	Initiated	SunTrust	Buy
Jun-19-18	Downgrade	B. Riley FBR, Inc.	Buy → Neutral
Feb-16-18	Initiated	B. Riley FBR, Inc.	Buy
Oct-23-17	Initiated	JMP Securities	Mkt Outperform
Oct-23-17	Initiated	JP Morgan	Overweight
Oct-23-17	Initiated	Nomura	Buy
Oct-23-17	Initiated	Piper Jaffray	Overweight

View All

Deciphera Pharmaceuticals Inc Stock (DCPH) Latest News

Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks Investment Research

Deciphera Pharmaceuticals, Inc. (DCPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks Investment Research

Why Is Biogen Inc. (BIIB) Up 2.6% Since Last Earnings Report?

Zacks Investment Research

Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Up 20.8% Since Last Earnings Report?

Zacks Investment Research

Wall Street Analysts Think Deciphera Pharmaceuticals, Inc. (DCPH) Could Surge 48.49%: Read This Before Placing a Bet

Zacks Investment Research

Wall Street Analysts Believe Deciphera Pharmaceuticals, Inc. (DCPH) Could Rally 59.63%: Here's is How to Trade

Zacks Investment Research

Deciphera Pharmaceuticals Inc Stock (DCPH) Financials Data

Deciphera Pharmaceuticals Inc (DCPH) Revenue 2024

DCPH reported a revenue (TTM) of $163.36 million for the quarter ending December 31, 2023, a +21.87% rise year-over-year.

Deciphera Pharmaceuticals Inc (DCPH) Net Income 2024

DCPH net income (TTM) was -$194.94 million for the quarter ending December 31, 2023, a -8.95% decrease year-over-year.

Deciphera Pharmaceuticals Inc (DCPH) Cash Flow 2024

DCPH recorded a free cash flow (TTM) of -$147.47 million for the quarter ending December 31, 2023, a +4.05% increase year-over-year.

Deciphera Pharmaceuticals Inc (DCPH) Earnings per Share 2024

DCPH earnings per share (TTM) was -$2.29 for the quarter ending December 31, 2023, a +10.20% growth year-over-year.

Deciphera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors. It is also developing immunokinase inhibitors comprising DCC-3014 that is in Phase I trial for treatment of solid tumors and hematologic malignancies; and Rebastinib, which is in Phase 1b trial to treat breast cancer, as well as to investigate in combination with chemotherapy and checkpoint inhibitors. The company was founded in 2003 and is headquartered in Waltham, Massachusetts.